A detailed history of Susquehanna International Group, LLP transactions in Arcellx, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 95,868 shares of ACLX stock, worth $8.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
95,868
Previous 39,153 144.85%
Holding current value
$8.42 Million
Previous $2.16 Million 270.6%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$50.91 - $86.61 $2.89 Million - $4.91 Million
56,715 Added 144.85%
95,868 $8.01 Million
Q2 2024

Aug 15, 2024

BUY
$49.74 - $66.98 $128,229 - $172,674
2,578 Added 7.05%
39,153 $2.16 Million
Q1 2024

May 07, 2024

BUY
$51.85 - $73.49 $699,663 - $991,674
13,494 Added 58.46%
36,575 $2.54 Million
Q4 2023

Feb 14, 2024

BUY
$31.75 - $57.99 $285,146 - $520,808
8,981 Added 63.7%
23,081 $1.28 Million
Q3 2023

Nov 14, 2023

SELL
$31.51 - $37.4 $63,083 - $74,874
-2,002 Reduced 12.43%
14,100 $505,000
Q2 2023

Aug 11, 2023

SELL
$27.49 - $46.9 $1.14 Million - $1.94 Million
-41,355 Reduced 71.98%
16,102 $509,000
Q1 2023

May 16, 2023

BUY
$26.92 - $33.94 $1.23 Million - $1.55 Million
45,694 Added 388.46%
57,457 $1.77 Million
Q4 2022

Feb 14, 2023

SELL
$17.18 - $33.0 $373,252 - $716,958
-21,726 Reduced 64.88%
11,763 $364,000
Q3 2022

Nov 14, 2022

BUY
$16.67 - $22.04 $314,512 - $415,828
18,867 Added 129.03%
33,489 $629,000
Q2 2022

Aug 15, 2022

BUY
$7.21 - $24.43 $180 - $610
25 Added 0.17%
14,622 $264,000
Q1 2022

May 16, 2022

BUY
$12.97 - $19.14 $189,323 - $279,386
14,597 New
14,597 $205,000

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.85B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.